{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=99",
    "query": {
      "intervention": "CTRL",
      "page": 99
    },
    "page_size": 10
  },
  "pagination": {
    "page": 99,
    "page_size": 10,
    "total_count": 26669,
    "total_pages": 2667,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=100&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=98&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T09:00:13.226Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00637728",
      "title": "Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anorexia",
        "Cachexia",
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "Megestrol acetate concentrated suspension 110 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Par Pharmaceutical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2006-06",
      "completion_date": "2006-09",
      "has_results": true,
      "last_update_posted_date": "2016-06-23",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cumberland",
          "state": "Maryland"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00637728"
    },
    {
      "nct_id": "NCT00679107",
      "title": "A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Degenerative Lumbar Spondylolisthesis"
      ],
      "interventions": [
        {
          "name": "Use of OP-1 Putty in Uninstrumented posterolateral fusion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Olympus Biotech Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "81 Years",
        "sex": "ALL",
        "summary": "18 Years to 81 Years"
      },
      "enrollment_count": 48,
      "start_date": "1999-06",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2011-06-10",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Royal Oak, Michigan + 2 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679107"
    },
    {
      "nct_id": "NCT05368571",
      "title": "CHOICES-TEEN Randomized Controlled Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Risk for an Alcohol-Exposed Pregnancy",
        "Risk for Marijuana-Exposed Pregnancy",
        "Risk for Substance-Exposed Pregnancy",
        "HIV Risk",
        "Sexually Transmitted Infection Risk"
      ],
      "interventions": [
        {
          "name": "CHOICES-TEEN",
          "type": "OTHER"
        },
        {
          "name": "Health and Life Skills Education",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Danielle Parrish",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "19 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 19 Years · Female only"
      },
      "enrollment_count": 400,
      "start_date": "2022-04-08",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05368571"
    },
    {
      "nct_id": "NCT06624644",
      "title": "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Melanoma (Skin Cancer)",
        "Melanoma Stage IIIB-IV",
        "Cutaneous Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "LNS8801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy (dacarbazine or temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Immunotherapy (Pembrolizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (nivolumab and relatlimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunotherapy (ipilimumab and nivolumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2025-08-06",
      "completion_date": "2031-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 9,
      "location_summary": "Newport Beach, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06624644"
    },
    {
      "nct_id": "NCT01939964",
      "title": "Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Wrinkles on Face and Neck Areas"
      ],
      "interventions": [
        {
          "name": "Activation Mist",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "California Allergy and Asthma Medical Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2013-11",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2013-09-11",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939964"
    },
    {
      "nct_id": "NCT03969901",
      "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Suspected or Documented Gram-negative Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "IMI/REL",
          "type": "DRUG"
        },
        {
          "name": "Active Control",
          "type": "DRUG"
        },
        {
          "name": "Oral Switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 115,
      "start_date": "2019-10-08",
      "completion_date": "2024-05-07",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Long Beach, California • San Diego, California + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03969901"
    },
    {
      "nct_id": "NCT06989801",
      "title": "Benefits of Outdoor Walks in Reducing Depressive Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "Urban Walk",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nature Walk",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Active Nature Walk",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2025-04-11",
      "completion_date": "2025-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989801"
    },
    {
      "nct_id": "NCT06777901",
      "title": "Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peripheral Arterial Diseases"
      ],
      "interventions": [
        {
          "name": "Auryon Atherectomy System",
          "type": "DEVICE"
        },
        {
          "name": "Balloon Angioplasty",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Angiodynamics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 224,
      "start_date": "2025-04-21",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • San Diego, California • Gray, Louisiana + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gray",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06777901"
    },
    {
      "nct_id": "NCT01640912",
      "title": "Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cicatrix",
        "Scar Prevention"
      ],
      "interventions": [
        {
          "name": "RXI-109",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RXi Pharmaceuticals, Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 50 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2012-06",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640912"
    },
    {
      "nct_id": "NCT03527212",
      "title": "A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Syndromes"
      ],
      "interventions": [
        {
          "name": "SJP-0035 0.001%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Senju Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2018-08-20",
      "completion_date": "2019-03-15",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-11-11T09:00:13.226Z",
      "location_count": 23,
      "location_summary": "Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03527212"
    }
  ]
}